Affymetrix and ScreenCell Sign Distribution Agreement for Tumor Cell Technology

Bers.

ScreenCell offers innovative devices that isolate and characterize a wide range of tumor cells, including mesenchymal cells, cancer stem cells, microembolii, and non-epithelial cancer cells, that other devices often fail to detect. ScreenCell devices also allow the collected cells to be grown in culture for drug screening or further genomics analysis. However, according to David Znaty, CEO, ScreenCell, the company wanted to diversify its portfolio and create devices that are not limited to the detection of cells.
“Our goal in designing ScreenCell technologies was to create a universal system, not limited to detection of cells of non-epithelial origin and free of any bias potentially linked to the use of antibodies for cell capture,” said Mr. Znaty. “Our goal is to provide a technology to support further research for use in personalized medicine by creating a broadly accessible, non-invasive evaluation of specific, potential therapeutic targets. We are excited to work with Affymetrix not just for their commercial strength, but because we believe strongly in our combined technologies.”

ScreenCell designs and produces technology that allows for the fast and effective filtering of Rare Circulating Cells for better cellular and molecular characterization. The company offers full range of point of care devices for use with in vitro Diagnostics (IVD) assays and platforms.

Affymetrix is a global provider of genomic analysis tools and education resources for the life science research community. Affymetrix technology is used by pharmaceutical, diagnostic, and biotechnology companies worldwide, as well as academic, government, and nonprofit research institutes.

Related Links:

Affymetrix, Inc.

ScreenCell